-

Piper Sandler Advises SK Capital on Sale of Niacet to Kerry

MINNEAPOLIS--(BUSINESS WIRE)--Piper Sandler & Co. chemicals & materials investment banking group (The Valence Group) announced today that it has advised SK Capital Partners on the sale of its portfolio company, Niacet Corporation, to Kerry Group plc for $1.015bn (€853m) on a cash-free, debt-free basis, subject to customary closing adjustments. Following the acquisition, Niacet will be integrated into Kerry’s global food protection and preservation platform.

The transaction is expected to close by the end of the third quarter of 2021, subject to customary closing conditions and regulatory approvals.

Niacet is a global market leader in technologies for preservation. It has clear leadership positions in Bakery and Pharma, and cost-effective low-sodium preservation systems for Meat and plant-based food across both conventional and clean label solutions. Niacet is differentiated by its proprietary drying and granulation process technologies in its key market categories of Bakery, Meat and Pharma. The business has customers in over 75 countries and key manufacturing sites in Niagara Falls (USA) and Tiel (Netherlands).

SK Capital is a private investment firm with a disciplined focus on the specialty materials, chemicals and pharmaceuticals sectors. SK Capital's portfolio of businesses generates revenues of approximately $11 billion annually, employs more than 16,000 people globally and operates 150 plants in 28 countries.

ABOUT PIPER SANDLER

Piper Sandler Companies (NYSE: PIPR) is a leading investment bank driven to help clients Realize the Power of Partnership®. Securities brokerage and investment banking services are offered in the U.S. through Piper Sandler & Co., member SIPC and NYSE; in the U.K. through Piper Sandler Ltd., authorized and regulated by the U.K. Financial Conduct Authority; and in Hong Kong through Piper Sandler Hong Kong Ltd., authorized and regulated by the Securities and Futures Commission. Private equity strategies and fixed income advisory services are offered through separately registered advisory affiliates.

Follow Piper Sandler: LinkedIn | Facebook | Twitter

©2021. Since 1895. Piper Sandler Companies. 800 Nicollet Mall, Minneapolis, Minnesota 55402-7036

Contacts

Pamela Steensland
Tel: 612 303-8185
pamela.steensland@psc.com

Piper Sandler Companies

NYSE:PIPR

Release Summary
Piper Sandler Advises SK Capital on Sale of Niacet to Kerry
$Cashtags

Contacts

Pamela Steensland
Tel: 612 303-8185
pamela.steensland@psc.com

More News From Piper Sandler Companies

Piper Sandler Strengthens Fixed Income Platform with the Addition of Distressed Debt and Special Asset Group

NEW YORK--(BUSINESS WIRE)--Piper Sandler Companies (NYSE: PIPR), a leading investment bank, is pleased to announce the additions of John Mori and Eric Friel as managing directors to lead a new group that will focus on distressed debt and special assets. Mori will be based in Greenwich and Friel will be in New York, both reporting to Michael Piper, head of fixed income at Piper Sandler. The distressed debt and special asset group will source and trade specialized credit products, including distr...

Piper Sandler Companies Reports First Quarter 2026 Results; Increases Quarterly Dividend to $0.20 Per Share

MINNEAPOLIS--(BUSINESS WIRE)--The complete earnings release can be found on the firm's website at pipersandler.com/earnings...

Piper Sandler Strengthens Healthcare Investment Banking Team with the Addition of Patrick McCormack

MINNEAPOLIS & SAN FRANCISCO--(BUSINESS WIRE)--Piper Sandler Companies (NYSE: PIPR), a leading investment bank, is pleased to announce the addition of Patrick McCormack, M.D. as a managing director in the healthcare investment banking group. McCormack will be based in San Francisco and focused on advising biopharma companies on mergers and acquisitions and capital-raising transactions. “We are excited to welcome Patrick to the healthcare investment banking team. His deep expertise advising bioph...
Back to Newsroom